I will start, and then I will ask my colleague Declan if he has anything to add regarding the reports, specifically.
If I understand correctly, the reports focus on products introduced in the past five or ten years, so products that have already been brought onto the market. These were major products, and the reports assumed that all of the products would be granted the highest level of IP protection. But that isn't the case in Europe. It doesn't work that way.
We must bear in mind that health research changes quickly. It is often said that tomorrow's research won't look like today's. The pipelines of yesterday or five years ago have changed considerably.